Arterra Bioscience Past Earnings Performance
Past criteria checks 2/6
Arterra Bioscience has been growing earnings at an average annual rate of 5.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 6.2% per year. Arterra Bioscience's return on equity is 9.8%, and it has net margins of 21.6%.
Key information
5.4%
Earnings growth rate
-6.7%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 6.2% |
| Return on equity | 9.8% |
| Net Margin | 21.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Arterra Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 5 | 1 | 2 | 0 |
| 31 Mar 23 | 5 | 1 | 1 | 0 |
| 31 Dec 22 | 5 | 1 | 1 | 0 |
| 30 Sep 22 | 5 | 1 | 1 | 0 |
| 30 Jun 22 | 5 | 1 | 1 | 0 |
| 31 Mar 22 | 5 | 1 | 1 | 0 |
| 31 Dec 21 | 5 | 1 | 1 | 0 |
| 30 Sep 21 | 5 | 1 | 1 | 0 |
| 30 Jun 21 | 4 | 1 | 1 | 0 |
| 31 Mar 21 | 4 | 1 | 1 | 0 |
| 31 Dec 20 | 4 | 1 | 1 | 0 |
| 30 Sep 20 | 4 | 1 | 1 | 0 |
| 30 Jun 20 | 4 | 1 | 1 | 0 |
| 31 Mar 20 | 4 | 1 | 1 | 0 |
| 31 Dec 19 | 4 | 1 | 1 | 0 |
| 30 Sep 19 | 3 | 1 | 1 | 0 |
| 30 Jun 19 | 3 | 1 | 1 | 0 |
| 31 Mar 19 | 3 | 1 | 1 | 0 |
| 31 Dec 18 | 2 | 1 | 1 | 0 |
| 31 Dec 17 | 2 | 1 | 1 | 0 |
Quality Earnings: ARBS has high quality earnings.
Growing Profit Margin: ARBS's current net profit margins (21.6%) are lower than last year (27.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARBS's earnings have grown by 5.4% per year over the past 5 years.
Accelerating Growth: ARBS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ARBS had negative earnings growth (-29.6%) over the past year, making it difficult to compare to the Biotechs industry average (-11.5%).
Return on Equity
High ROE: ARBS's Return on Equity (9.8%) is considered low.